The biosim­i­lar pack is grow­ing around Roche’s all-star trio, look­ing to rip in­to a $21B fran­chise

Roche will get an­oth­er re­minder this week about just how im­por­tant its late-stage pipeline is these days.

Thurs­day, the FDA’s com­mit­tee of out­side can­cer ex­perts will field a pair of ap­pli­ca­tions for two new biosim­i­lars of Avastin and Her­ceptin, two long­time drug fran­chis­es that last year pro­vid­ed about $14 bil­lion in rev­enue to the Swiss phar­ma gi­ant. And ac­cord­ing to the FDA in­sid­ers who did the in­ter­nal re­views, both of these copy­cats are ready to go.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER